CHINA STOCKS
- by market
- AIM (London)
- AMEX
- Frankfurt Stock Exchange
- London Stock Exchange
- NASDAQ
- New York Stock Exchange
- OTC Bulletin Board
- Toronto Stock Exchange
SECTORS
- Aerospace
- Agriculture
- Apparel
- Auto
- Beauty culture
- Capital
- chemical industry
- Cleantech
- clothing
- Communication
- Construction/materials
- Consumer/leisure
- Decoration
- Education
- Electricity storage/transmission
- Electronics
- Energy
- Finance
- Food/beverage
- Forestry/paper
- Funds
- Gold
- Insurance
- IT/software
- Jewelry
- Logistics
- Manufacturing
- Media
- Military
- Mining
- Packaging
- Pharma/healthcare
- Photographic equipment
- Rare earths
- Real estate
- Steel
- Telecoms
- Travel/hotels
- Utilities
- Wholesale
QFII FUNDS
EVENTS
ABOUT US
NEWSLETTER

China Aoxing Pharmaceutical Company

China Aoxing Pharmaceutical Company, Inc. is a pharmaceutical company located in China specializing in research, development, manufacturing and distribution of a variety of narcotics and pain-management products.

It also has a strategic alliance with American Oriental Bioengineering, Inc. (NYSE: AOB) to develop and market various narcotic drugs in China

See more information about China Aoxing Pharmaceutical Company

China Aoxing Pharma gets renewal of GMP certification for capsule production facility

2009-07-24 by Proactive Investors

China Aoxing Pharmaceutical Co Inc, specialised in research, development, manufacturing and distribution of narcotic and pain management products, said the Chinese State Food and Drug Administration has renewed the Good Manufacturing Practice (GMP) certification for its capsule formulation and packaging production facility.

The certificate is valid for five years and was issued by the SFDA following a site inspection.

Good Manufacturing Practice is a term that is recognized worldwide for the control and management of manufacturing and quality control testing of foods, pharmaceutical products, and medical devices.

According to the National Medicine Administration Law of the People's Republic of China, all pharmaceutical manufacturers must pass an examination every five years to renew their GMP Certificates.

"GMP compliance is the gold standard in quality assurance in the life science industry. We are happy to obtain the renewal of the GMP certificate for capsule products," said Juan Yue Han, chairman and the CEO of China Aoxing.

China Aoxing has a strategic alliance with American Oriental Bioengineering Inc (NYSE: AOB) to develop and market various narcotic drugs in China. Headquartered in Shijiazhuang City outside of Beijing, China Aoxing has China's largest and the most advanced manufacturing facility for highly regulated narcotic medicines.